DYN logo

DYN Dyne Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$15.87
-0.15 (-0.94%)

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, …

Market Cap: $2.97Bwww.dyne-tx.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
50
2 mentions
—
60d
50
3 mentions
—
90d
54
7 mentions
—
news: 7

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 1Buy 10Hold 2Sell 1Strong Sell 0
Avg price target$36.88+132.4%
Low $26Median $36.5High $50
Current Consensus

Revenue

$0.00-100.00%
$0.00$263.67M$527.33M$791.00M
Dec 2015Sep 2026

Analyst Estimates

FY2025
$-3.50
$-3.59–$-3.38
10 analysts
FY2026
$-3.81
$-3.96–$-3.14
11 analysts
FY2027
$-3.66
$-4.44–$-2.77
13 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
John G. Cox
Sector
Healthcare
Industry
Biotechnology
Employees
289
Beta
1.21
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
3.33
www.dyne-tx.com